Literature DB >> 3082494

Topical administration of 1,25-dihydroxyvitamin D3 for psoriasis: report of five cases.

S Morimoto, T Onishi, S Imanaka, H Yukawa, T Kozuka, Y Kitano, K Yoshikawa, Y Kumahara.   

Abstract

The effects of topical administration of 1,25-dihydroxyvitamin D3, as 0.1 and 0.5 microgram per g base, and control base applied to contralateral skin lesions in five patients with persistent psoriasis were compared. In all five, definite and in some cases remarkable improvement of the lesions was seen when 1,25-dihydroxyvitamin D3 at concentration of 0.5 microgram per g base was applied for two to five weeks. No local or systemic toxicity was detected in any patient. Although the mechanism of the improvement is yet to be elucidated, these results show the possible effectiveness of topical 1,25-dihydroxyvitamin D3 on psoriatic skin lesions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082494     DOI: 10.1007/bf02556840

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  20 in total

1.  The approach to psoriasis.

Authors:  J T INGRAM
Journal:  Br Med J       Date:  1953-09-12

2.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.

Authors:  J A Parrish; T B Fitzpatrick; L Tanenbaum; M A Pathak
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

3.  Psoriasis exacerbated by hypoparathyroidism with hypocalcaemia.

Authors:  G Risum
Journal:  Br J Dermatol       Date:  1973-09       Impact factor: 9.302

4.  Topical administration of Vitamin A acid for ichthyosiform dermatoses and psoriasis.

Authors:  P Frost; G D Weinstein
Journal:  JAMA       Date:  1969-03-10       Impact factor: 56.272

5.  1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells.

Authors:  C Miyaura; E Abe; T Kuribayashi; H Tanaka; K Konno; Y Nishii; T Suda
Journal:  Biochem Biophys Res Commun       Date:  1981-10-15       Impact factor: 3.575

6.  Normal serum 1,25-dihydroxyvitamin D in patients with medullary carcinoma of the thyroid.

Authors:  S Lee; S Morimoto; T Onishi; M Tsuji; Y Okada; Y Seino; M Ishida; K Yamaoka; S Takai; A Miyauchi; Y Kumahara
Journal:  J Clin Endocrinol Metab       Date:  1982-08       Impact factor: 5.958

7.  1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture.

Authors:  K Colston; M J Colston; D Feldman
Journal:  Endocrinology       Date:  1981-03       Impact factor: 4.736

8.  Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies.

Authors:  D Feldman; T Chen; M Hirst; K Colston; M Karasek; C Cone
Journal:  J Clin Endocrinol Metab       Date:  1980-12       Impact factor: 5.958

9.  The effect of oestrogens on human calcitonin secretion after calcium infusion in elderly female subjects.

Authors:  S Morimoto; M Tsuji; Y Okada; T Onishi; Y Kumahara
Journal:  Clin Endocrinol (Oxf)       Date:  1980-08       Impact factor: 3.478

10.  Interaction of 1,25-dihydroxyvitamin-D3 with keratinocytes and fibroblasts from skin of normal subjects and a subject with vitamin-D-dependent rickets, type II: a model for study of the mode of action of 1,25-dihydroxyvitamin D3.

Authors:  T L Clemens; J S Adams; N Horiuchi; B A Gilchrest; H Cho; Y Tsuchiya; N Matsuo; T Suda; M F Holick
Journal:  J Clin Endocrinol Metab       Date:  1983-04       Impact factor: 5.958

View more
  7 in total

1.  Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study.

Authors:  S Takamoto; T Onishi; S Morimoto; S Imanaka; S Yukawa; T Kozuka; Y Kitano; Y Seino; Y Kumahara
Journal:  Calcif Tissue Int       Date:  1986-12       Impact factor: 4.333

2.  Treatment of psoriasis vulgaris by oral administration of 1 alpha-hydroxyvitamin D3--open-design study.

Authors:  S Morimoto; K Yoshikawa; T Kozuka; Y Kitano; S Imanaka; K Fukuo; E Koh; T Onishi; Y Kumahara
Journal:  Calcif Tissue Int       Date:  1986-09       Impact factor: 4.333

Review 3.  Vitamin D deficiency in early life and the potential programming of cardiovascular disease in adulthood.

Authors:  Oksan Gezmish; Mary Jane Black
Journal:  J Cardiovasc Transl Res       Date:  2013-05-30       Impact factor: 4.132

4.  Vitamin D3 inhibits proliferation and increases c-myc expression in fibroblasts from psoriatic patients.

Authors:  M Casado; M Martin; A Muñoz; J Bernal
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

5.  Topical application of 1,25-dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children.

Authors:  G Saggese; G Federico; R Battini
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

Review 6.  Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications.

Authors:  Patrick J McCullough; William P McCullough; Douglas Lehrer; Jeffrey B Travers; Steven J Repas
Journal:  Nutrients       Date:  2021-04-29       Impact factor: 5.717

Review 7.  Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy.

Authors:  Anna A Brożyna; Radomir M Slominski; Bogusław Nedoszytko; Michal A Zmijewski; Andrzej T Slominski
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.